Author:
ALKAN ÇEVİKER Sevil,ŞENER Alper,YÜKSEL Cihan,ÖNDER Taylan,AKÇA Anıl,VURUCU Servan,GÜÇLÜ Safiye
Publisher
Journal of Emergency Medicine Case Reports
Reference17 articles.
1. 1. Khambholja K, Asudani D. Potential repurposing of Favipiravir in COVID-19 outbreak based on current evidence. Travel Med Infect Dis. 2020;35:101710. doi: 10.1016/j.tmaid.2020.101710.
2. 2. Wang M, Cao R, zhang L et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30:269-71.
3. 3. McCreary EK, pogue M, on behalf of the Society of Infectious Diseases pharmacists. COVID-19 Treatment: a review of early and emerging options. OFID . 2020;7:ofaa105.
4. 4. Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, et al. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. Engineering (Beijing). 2020. doi: 10.1016/j. eng.2020.03.007
5. 5. Galván Casas C, Català A, Carretero Hernández G, Rodríguez-Jiménez P, Fernández-Nieto D, Rodríguez-Villa Lario A, et al. Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. Br J Dermatol. 2020;183(1):71-77. doi: 10.1111/bjd.19163.
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献